Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial

Background: Patients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA(®)) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Biermasz, Nienke, Fleseriu, Maria, Dreval, Akexander V, Pokramovich, Yulia, Bondar, Irina, Isaeva, Elena, Molitch, Mark E, Macut, Djuro P, Leonova, Nina, Raverot, Gerald, Gilgun-Sherki, Yossi, Ludlam, William H, Patou, Gary, Haviv, Asi, Gordon, Murray B, Urbanavicius, Vaidotas, Knispelis, Robertas, Melmed, Shlomo, Strasburger, Christian J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090610/
http://dx.doi.org/10.1210/jendso/bvab048.1065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090610/
http://dx.doi.org/10.1210/jendso/bvab048.1065

Ejemplares similares